The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $7.99 in the prior trading day, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $8.00, up 0.13%. In other words, the price has increased by $0.13 from its previous closing price. On the day, 0.84 million shares were traded. OCUL stock price reached its highest trading level at $8.15 during the session, while it also had its lowest trading level at $7.86.
Ratios:
Our goal is to gain a better understanding of OCUL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.55 and its Current Ratio is at 16.64. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on June 20, 2024, Upgraded its rating to Buy and sets its target price to $11 from $7 previously.
On February 09, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $15.BofA Securities initiated its Buy rating on February 09, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 07 ’24 when RABIA OZDEN bought 15,000 shares for $8.50 per share.
ANTONY MATTESSICH bought 23,979 shares of OCUL for $196,498 on Aug 01 ’24. On May 23 ’24, another insider, Dugel Pravin, who serves as the insider of the company, sold 21,626 shares for $5.79 each. As a result, the insider received 125,215 and left with 833,353 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1247376000 and an Enterprise Value of 862571456. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.42 while its Price-to-Book (P/B) ratio in mrq is 3.30. Its current Enterprise Value per Revenue stands at 14.118 whereas that against EBITDA is -7.789.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.31, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is 15.28%, while the 200-Day Moving Average is calculated to be 33.84%.
Shares Statistics:
The stock has traded on average 2.03M shares per day over the past 3-months and 1292270 shares per day over the last 10 days, according to various share statistics. A total of 155.92M shares are outstanding, with a floating share count of 135.46M. Insiders hold about 13.13% of the company’s shares, while institutions hold 69.12% stake in the company. Shares short for OCUL as of 1722384000 were 19087496 with a Short Ratio of 9.42, compared to 1719532800 on 21339425. Therefore, it implies a Short% of Shares Outstanding of 19087496 and a Short% of Float of 12.3100005.
